A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis.

Trial Profile

A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2010

At a glance

  • Drugs Fedratinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Oct 2009 Actual patient number (59) added as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2009 Planned end date changed from 1 Mar 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top